Stone House Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.27K Buy
54
+43
+391% +$2.51K ﹤0.01% 518
2025
Q4
$593 Buy
+11
New +$529 ﹤0.01% 708
2025
Q2
Sell
-1,050
Closed -$64K 526
2025
Q1
$64K Buy
+1,050
New +$61.2K 0.01% 131
2024
Q3
Sell
-79
Closed -$3.28K 386
2024
Q2
$3.28K Sell
79
-53
-40% -$2.37K ﹤0.01% 307
2024
Q1
$7.17K Buy
+132
New +$6.72K ﹤0.01% 259

Other funds holding BMY

Stone House Investment Management's BMY Position: Q1 2026 in Review

Stone House Investment Management increased its Bristol-Myers Squibb (BMY) stake by 391% in Q1 2026, buying an estimated $2.51K and bringing the position to 54 shares worth $3.27K. The position accounts for ﹤0.01% of the portfolio, ranked #518.

Stone House Investment Management first reported a position in BMY in Q1 2024 and has held it in 5 quarters since. The position peaked at $64K in Q1 2025. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Stone House Investment Management held 54 shares of Bristol-Myers Squibb worth $3.27K as of Q1 2026.
  • Stone House Investment Management bought 43 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.51K.
  • Bristol-Myers Squibb made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #518 holding.
  • Stone House Investment Management first reported a position in Bristol-Myers Squibb in Q1 2024 and has held it in 5 quarters since.
  • Stone House Investment Management's Bristol-Myers Squibb position peaked at $64K in Q1 2025.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.